Securing the diagnosis of HRS-AKI: implications for current therapies

References

• Singal AK, Jalan R. Terlipressin for hepatorenal syndrome: opportunities and challenges. Lancet Gastroenterol Hepatol. 2023;8(2):104–106. doi: 10.1016/S2468-1253(22)00377-6
   PubMed Web of Science ®Google Scholar
• Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014–48. doi: 10.1002/hep.31884. PMID: 33942342.
   PubMed Web of Science ®Google Scholar
• Nadim MK, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis. N Engl J Med. 2023;388(8):733–45. doi: 10.1056/NEJMra2215289
   PubMed Web of Science ®Google Scholar
• Angeli P, Bernardi M, Villanueva C. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal Of Hepatology. 2018;69(2):406–60. doi: 10.1016/j.jhep.2018.03.024
   PubMed Web of Science ®Google Scholar
• Curry MP, Vargas HE, Befeler AS, et al. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies. Hepatol Commun. 2023;7(1):e1307. doi: 10.1097/01.HC9.0000897228.91307.0c
   PubMed Web of Science ®Google Scholar
• Wong F, Leung W, Al Beshir M, et al. Outcomes of patient s with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl. 2015;21(3):300–307. doi: 10.1002/lt.24049
   PubMed Web of Science ®Google Scholar
• Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315–21. doi: 10.1016/j.jhep.2010.11.020
   PubMed Web of Science ®Google Scholar
• Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352–1359. doi: 10.1053/j.gastro.2008.02.024
   PubMed Web of Science ®Google Scholar
• Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–1318. doi: 10.1136/gut.2006.107789
   PubMed Web of Science ®Google Scholar
• Francoz C, Glotz D, Moreau R, et al. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52(4):605–613. doi: 10.1016/j.jhep.2009.11.025
   PubMed Web of Science ®Google Scholar
• Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003;41(2):269–278. doi: 10.1053/ajkd.2003.50035
   PubMed Web of Science ®Google Scholar
• Rodríguez E, Elia C, Solà E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955–961. doi: 10.1016/j.jhep.2013.12.032
   PubMed Web of Science ®Google Scholar
• Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004;15(6):1597–1605. doi: 10.1097/01.ASN.0000130340.93930.DD
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–3370. doi: 10.1681/ASN.2004090740
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi: 10.1186/cc5713
   PubMed Web of Science ®Google Scholar
• Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84. doi: 10.1159/000339789. Epub 2012 Aug 7. PMID: 22890468.
   Google Scholar
• Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of ascites. J Hepatol. 2015;62(4):968–974. doi: 10.1016/j.jhep.2014.12.029
   PubMed Web of Science ®Google Scholar
• Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of ascites (ICA) consensus document. J Hepatol. 2019;71(4):811–822. doi: 10.1016/j.jhep.2019.07.002
   PubMed Web of Science ®Google Scholar
• Altamirano J, Fagundes C, Dominguez M, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2012;10(1):65–71.e3. doi: 10.1016/j.cgh.2011.09.011
   PubMed Web of Science ®Google Scholar
• Wong F, O’Leary JG, Reddy KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology. 2013;145(6):1280–8.e1. doi: 10.1053/j.gastro.2013.08.051
   PubMed Web of Science ®Google Scholar
• Piano S, Rosi S, Maresio G, et al. Evaluation of the acute kidney injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013;59(3):482–489. doi: 10.1016/j.jhep.2013.03.039
   PubMed Web of Science ®Google Scholar
• Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57(2):753–762. doi: 10.1002/hep.25735
   PubMed Web of Science ®Google Scholar
• Amathieu R, Al-Khafaji A, Sileanu FE, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatology. 2017;66(5):1592–1600. doi: 10.1002/hep.29303
   PubMed Web of Science ®Google Scholar
• Wong F, Kwo P. Practical management of HRS-AKI in the Era of terlipressin: what the Gastroenterologist Needs to Know. Am J Gastroenterol. 2023;118(6):915–920. doi: 10.14309/ajg.0000000000002115
   PubMed Web of Science ®Google Scholar
• Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41(6):1282–1289. doi: 10.1002/hep.20687
   PubMed Web of Science ®Google Scholar
• Martín-Llahí M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011;140(2):488–96.e4. doi: 10.1053/j.gastro.2010.07.043
   PubMed Web of Science ®Google Scholar
• Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51(2):576–584. doi: 10.1002/hep.23286
   PubMed Web of Science ®Google Scholar
• Gluud LL, Christensen K, Christensen E, et al. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. Sep;12(9):CD005162. doi: 10.1002/14651858
   Google Scholar
• Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(2):94–102. doi: 10.1016/S2468-1253(16)30157-1
   PubMed Web of Science ®Google Scholar
• Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62(2):567–74. doi: 10.1002/hep.27709
   PubMed Web of Science ®Google Scholar
• Allegretti AS, Subramanian RM, Francoz C, et al. Respiratory events with terlipressin and albumin in hepatorenal syndrome: a review and clinical guidance. Liver Int. 2022;42(10):2124–2130. doi: 10.1111/liv.15367
   PubMed Web of Science ®Google Scholar
• Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Of Systematic Reviews. 2017;2017(9):CD011532. doi: 10.1002/14651858.CD011532.pub2
   Google Scholar
• Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836–1846. doi: 10.1002/hep.26338
   PubMed Web of Science ®Google Scholar
• China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808–817. doi: 10.1056/NEJMoa2022166
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Reddy KR, Garcia-Tsao G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology. 2018;67(6):2367–2374. doi: 10.1002/hep.29773
   PubMed Web of Science ®Google Scholar
• Rogal SS, Hansen L, Patel A, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022;76(3):819–853. doi: 10.1002/hep.32378
   PubMed Web of Science ®Google Scholar
• Thomson MJ, Taylor A, Sharma P, et al. Limited progress in hepatorenal syndrome (HRS) reversal and survival 2002–2018: a Systematic review and meta-analysis. Dig Dis Sci. 2020;65(5):1539–1548. doi: 10.1007/s10620-019-05858-2
   PubMed Web of Science ®Google Scholar
• Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2013;60(2):622–632. doi: 10.1002/hep.26980
   Web of Science ®Google Scholar
• Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology. 2019;70(1):319–333. doi: 10.1002/hep.30592
   PubMed Web of Science ®Google Scholar
• Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622–632. doi: 10.1002/hep.26980
   PubMed Web of Science ®Google Scholar
• Ariza X, Solà E, Elia C, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One. 2015;10(6):e0128145. doi: 10.1371/journal.pone.0128145
   PubMed Web of Science ®Google Scholar
• Allegretti AS, Solà E, Ginès P. Clinical application of kidney biomarkers in cirrhosis. Am J Kidney Dis. 2020;76(5):710–719. doi: 10.1053/j.ajkd.2020.03.016
   PubMed Web of Science ®Google Scholar
• Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–828. doi: 10.1056/NEJMoa2008290
   PubMed Web of Science ®Google Scholar
• Belcher JM, Parada XV, Simonettom DA, et al. Terlipressin and the treatment of hepatorenal syndrome: how the CONFIRM trial moves the story forward. Am J Kidney Dis. 2022;79(5):737–745. doi: 10.1053/j.ajkd.2021.08.016
   PubMed Web of Science ®Google Scholar
• Velez JCQ, Petkovich B, Karakala N, et al. Point-of-care echocardiography unveils misclassification of acute kidney injury as hepatorenal syndrome. Am J Nephrol. 2019;50(3):204–211. doi: 10.1159/000501299
   PubMed Web of Science ®Google Scholar
• Piano S, Gambino C, Vettore E, et al. Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome. Hepatology. 2021;73(5):1909–1919. doi: 10.1002/hep.31529
   PubMed Web of Science ®Google Scholar
• Durand F, Francoz C, Asrani SK, et al. Acute kidney injury after liver transplantation. Transplantation. 2018;102(10):1636–1649. doi: 10.1097/TP.0000000000002305
   PubMed Web of Science ®Google Scholar
• Cillo U, Burra P, Mazzaferro V, et al. A Multistep, consensus-based approach to organ allocation in liver transplantation: toward a “blended principle Model”. Am J Transplant. 2015;15(10):2552–2561. doi: 10.1111/ajt.13408
   PubMed Web of Science ®Google Scholar
• Piano S, Schmidt HH, Ariza X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018;16(11):1792–800.e3. doi: 10.1016/j.cgh.2018.01.035
   PubMed Web of Science ®Google Scholar